Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Galvus (Vildagliptin) on interleukin-6 in Diabetic Foot Ulcer

Trial Profile

Effects of Galvus (Vildagliptin) on interleukin-6 in Diabetic Foot Ulcer

Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs Vildagliptin (Primary) ; Metformin
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GIED
  • Most Recent Events

    • 03 Sep 2018 Planned End Date changed from 30 Apr 2016 to 30 Jul 2022.
    • 19 Mar 2015 Status changed from not yet recruiting to recruiting, according to the Australian New Zealand Clinical Trials Registry record.
    • 28 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top